Validation of the Partin Nomogram for Prostate Cancer in a National Sample

No AccessJournal of UrologyAdult Urology1 Jan 2010Validation of the Partin Nomogram for Prostate Cancer in a National Sample James B. Yu, Danil V. Makarov, Richa Sharma, Richard E. Peschel, Alan W. Partin, and Cary P. Gross James B. YuJames B. Yu Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut More articles by this author , Danil V. MakarovDanil V. Makarov Robert Wood Johnson Clinical Scholars Program, Yale School of Medicine, New Haven, Connecticut Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut More articles by this author , Richa SharmaRicha Sharma School of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut More articles by this author , Richard E. PeschelRichard E. Peschel Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut More articles by this author , Alan W. PartinAlan W. Partin The Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author , and Cary P. GrossCary P. Gross Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut Robert Wood Johnson Clinical Scholars Program, Yale School of Medicine, New Haven, Connecticut More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.08.143AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The Partin tables are a nomogram that is widely used to discriminate prostate cancer pathological stages, given common preoperative clinical characteristics. The nomogram is based on patients undergoing radical prostatectomy at The Johns Hopkins Medical Institutions. We validated the Partin tables in a large, population based sample. Materials and Methods: The National Cancer Institute Surveillance, Epidemiology and End Results database was used to identify patients treated from 2004 to 2005 who underwent radical prostatectomy. The 2007 Partin tables were used to estimate the prevalence of positive lymph nodes, seminal vesicle invasion, extraprostatic extension and organ confined disease in men with prostate cancer in the database using clinical stage, preoperative prostate specific antigen and Gleason score. The discriminative ability of the tables was explored by constructing ROC curves. Results: We identified 11,185 men who underwent radical prostatectomy for prostate cancer in 2004 to 2005. The Partin tables discriminated well between patient groups at risk for positive lymph nodes and seminal vesicle invasion (AUC 0.77 and 0.74, respectively). The discrimination of extraprostatic extension and organ confined disease was more limited (AUC 0.62 and 0.68, respectively). The AUC for positive lymph nodes was 0.78 in white men, 0.73 in black men and 0.83 in Asian/Pacific Islander men (p = 0.17). The AUC for positive lymph nodes in men 61 years old or younger was 0.80 vs 0.74 in men older than 61 years (p = 0.03). Conclusions: The Partin tables showed excellent discrimination for seminal vesicle invasion and positive lymph nodes. Discrimination of extraprostatic extension and organ confined disease was more limited. The Partin tables performed best in young men. References 1 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar 2 : The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol1993; 150: 110. Abstract, Google Scholar 3 : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA1997; 277: 1445. Google Scholar 4 : Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology2001; 58: 843. Google Scholar 5 : Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin Tables) based on cases from 2000 to 2005. Urology2007; 69: 1095. Google Scholar 6 : Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am2001; 28: 555. Google Scholar 7 : The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology2008; 71: 151. Google Scholar 8 : How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population?: Results of the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol2002; 167: 1653. Link, Google Scholar 9 : Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol2000; 164: 1591. Link, Google Scholar 10 : Comparison of accuracy between Partin tables of 1997 and 2001 to predict final pathologic stage in clinically localized prostate cancer. J Urol2004; 171: 177. Link, Google Scholar 11 : External validation of the updated Partin tables in a cohort of North American men. J Urol2008; 180: 898. Link, Google Scholar 12 : Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. Eur J Surg Oncol2009; 35: 123. Google Scholar 13 : External validation of the updated Partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys2009; 73: 347. Google Scholar 14 Surveillance, Epidemiology, and End Results Program Limited-Use Data (1973–2005), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission (www.seer.cancer.gov). Google Scholar 15 National Cancer Institute: Collaborative Staging Manual and Coding Instructions. http://seer.cancer.gov/tools/collabstaging/index.html. Accessed August 9, 2008. Google Scholar 16 : Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/ml and lower. Cancer2008; 113: 2695. Google Scholar 17 : Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988; 44: 837. Google Scholar 18 : Verification of forecasts expressed in terms of probabilities. Mon Wea Rev1950; 78: 1. Google Scholar 19 : Tumor thickness predicts a five-year survival equally as well as more complex prognostic model. Evidence Based Oncol2000; 1: 10. Google Scholar 20 : Investigating black-white differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer2008; 123: 430. Google Scholar 21 Unequal Treatment, Confronting Racial and Ethnic Disparities in Healthcare: Institute of Medicine. Washington, D.C: National Academies Press2001. Google Scholar 22 : Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst2002; 94: 981. Google Scholar 23 : Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer2003; 97: 56. Google Scholar 24 : Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys1995; 32: 479. Google Scholar 25 : Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol2005; 174: 2181. Link, Google Scholar 26 : Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol2008; 180: 571. Link, Google Scholar 27 : Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol1996; 14: 1770. Google Scholar 28 : PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology1689; 109. Google Scholar 29 : Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int2006; 98: 788. Google Scholar 30 : Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology2008; 71: 141. Google Scholar © 2010 by American Urological AssociationFiguresReferencesRelatedDetailsCited byÖtleş E, Denton B, Qu B, Murali A, Merdan S, Auffenberg G, Hiller S, Lane B, George A and Singh K (2021) Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National CohortsJournal of Urology, VOL. 207, NO. 2, (358-366), Online publication date: 1-Feb-2022. Volume 183Issue 1January 2010Page: 105-111 Advertisement Copyright & Permissions© 2010 by American Urological AssociationKeywordsneoplasm stagingnomogramsprostateSEER programprostatic neoplasmsMetricsAuthor Information James B. Yu Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut More articles by this author Danil V. Makarov Robert Wood Johnson Clinical Scholars Program, Yale School of Medicine, New Haven, Connecticut Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut More articles by this author Richa Sharma School of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut More articles by this author Richard E. Peschel Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut More articles by this author Alan W. Partin The Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Cary P. Gross Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut Robert Wood Johnson Clinical Scholars Program, Yale School of Medicine, New Haven, Connecticut More articles by this author Expand All Advertisement PDF downloadLoading ...